Filter articles using the following links

GenSight Biologics Reports Full Year 2017 Financial Results

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

Phacilitate Cell & Gene Therapy World, Miami, US

Oddo BHF Forum, Lyon, France

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

JP Morgan 36th Annual Healthcare Conference, San Francisco (CA), USA

Guggenheim Securities 5th Annual Boston Healthcare Conference 2017, Boston, MA, USA

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)